Date: 2019-01-22
Type of information: Nomination
Compound: general counsel
Company: Voyager Therapeutics (USA-MA)
Therapeutic area: Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 22, 2019, Voyager Therapeutics announced the appointment of Robert Hesslein as general counsel. Mr. Hesslein’s experience includes more than 25 years as an in-house attorney leading and building legal organizations within the biotechnology industry, with specific expertise in domestic and international commercial law, securities and public company reporting, medical data privacy, as well as licensing and business development collaborations.
- Mr. Hesslein expects to begin working at Voyager in early April. Mr. Hesslein is joining Voyager from Foundation Medicine (acquired by Roche in July 2018), where he served as senior vice president, general counsel and chief compliance officer since 2012, responsible for managing corporate governance and all legal matters related to Foundation Medicine’s business including commercial, corporate and business development, compliance, and research and development functions. Prior to Foundation Medicine, Mr. Hesslein was a senior vice president and deputy general counsel at Genzyme Corporation (acquired by Sanofi in April 2011), serving in increasingly senior roles for 16 years, managing the legal support for many of Genzyme's most significant transactions and establishing and leading Genzyme's legal support outside of the U.S. Mr. Hesslein began his legal career at Csaplar & Bok (acquired by Gaston & Snow in 1990), a Boston-based law firm where he spent eight years as an associate and four years as a partner. Mr. Hesslein earned a B.A. from Yale University and received his J.D. from The Cornell Law School.
Financial terms:
Latest news:
Is general: Yes
